Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Ignacio Martin-Loeches, Jean François Timsit, Marin H. Kollef, Richard G. Wunderink, Nobuaki Shime, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Christopher J. Bruno, Jennifer A. Huntington, Gina Lin, Erin H. Jensen, Mary Motyl, Brian Yu, Davis Gates, Joan R. Butterton, Elizabeth G. Rhee*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia'. Together they form a unique fingerprint.

INIS

Immunology and Microbiology